Recent News

• 09.10.2025 - Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand
• 08.18.2025 - Waldencast Announces Strong Progress on Business Priorities for H1 2025 and Initiatives to Drive Transformation
• 07.23.2025 - Waldencast Acquires Novaestiq Corp. and U.S. Rights to Leading Injectable Hyaluronic Acid Gel Line, Saypha®, Under the Obagi Medical Brand
• 05.14.2025 - Waldencast plc First Quarter Fiscal 2025 Earnings Call
• 05.13.2025 - Waldencast Reports Q1 2025 Financial Results
• 05.06.2025 - Waldencast plc Announces First Quarter Fiscal 2025 Results Conference Call and Webcast
• 03.19.2025 - Jonna Kim

Recent Filings

• 09.04.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.19.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.18.2025 - EX-99.1 EX-99.1
• 08.18.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.31.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 07.23.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 07.23.2025 - EX-99.1 EX-99.1
• 05.19.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.14.2025 - EX-99.1 EX-99.1